Skip to main content

Table 2 The percentage of patients with HbA1c levels of < 7.0% and daily insulin reduction of ≥ 50% at 9–48 weeks of follow-up

From: Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial

 

UC-MSCS (% of patients)

PLACEBO (% of patients)

p-value

9 weeks

8.89

2.27

0.3607

20 weeks

15.56

9.09

0.3542

32 weeks

15.56

9.09

0.3542

48 weeks

20.00

4.55

0.0268